• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Bellicum Pharmaceuticals Inc.

    3/1/24 3:13:45 PM ET
    $BLCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLCM alert in real time by email
    15-12G 1 n3936_x25-1512g.htm 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number: 001-36783 

     

    Bellicum Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)  

     

    3730 Kirby Drive, Suite 1200

    Houston, TX 77098

    (281) 454-3424

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, par value $0.01 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

         
    Rule 12g-4(a)(1)   ☒
    Rule 12g-4(a)(2)   ☐
    Rule 12h-3(b)(1)(i)   ☒
    Rule 12h-3(b)(1)(ii)   ☐
    Rule 15d-6   ☐
    Rule 15d-22(b)   ☐

    Approximate number of holders of record as of the certification or notice date: Less than 300

     

     

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, Bellicum Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

                 
            BELLICUM PHARMACEUTICALS, INC.
           
    Date: March 1, 2024       By:  

    /s/ Dave Maggio

            Name:   Dave Maggio
            Title:   Chief Executive Officer

     

     

     

    Get the next $BLCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLCM

    DatePrice TargetRatingAnalyst
    2/16/2022$5.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $BLCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives

      HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company's assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most recent patient treated in the Phase 1/2 trial of BPX-601 in metastatic castration-resistant prostate cancer (mCRPC) experienced serious immune-mediated adverse events including Grade 4 cytokine rel

      3/14/23 4:30:00 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium

      Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and bone involvement HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled "Early Results from a Phase 1, Multicent

      2/16/23 7:30:00 AM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.14 per share and vest over four years, with 25% of the shares vesting on the one-year a

      1/31/23 4:36:38 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLCM
    Leadership Updates

    Live Leadership Updates

    See more
    • Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update

      - Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief Development Officer effective December 1, 2021 - HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2021 and provided an operational update. "In the third quarter, Bellicum broadened the potential impact of its CaspaCIDe technology through an additional licensing agreement with MD Anderson," said Rick Fair, President and

      11/4/21 4:05:00 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLCM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Bellicum Pharmaceuticals Inc.

      15-12G - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)

      3/1/24 3:13:45 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Bellicum Pharmaceuticals Inc.

      EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)

      2/27/24 12:16:02 AM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Bellicum Pharmaceuticals Inc.

      EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)

      2/27/24 12:18:15 AM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Bellicum Pharmaceuticals with a new price target

      Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals with a rating of Buy and set a new price target of $5.00

      2/16/22 7:20:35 AM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp exercised 2,116,349 in-the-money shares at a strike of $0.00 (SEC Form 4)

      4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)

      11/24/23 1:39:11 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Baker Bros. Advisors Lp claimed ownership of 249,123 shares

      3 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)

      5/5/23 4:03:19 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Huber Reid M converted options into 80,968 shares, increasing direct ownership by 123% to 146,951 units (Amendment)

      4/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)

      1/20/23 2:24:51 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bellicum Pharmaceuticals Inc. (Amendment)

      SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)

      2/14/24 6:00:57 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bellicum Pharmaceuticals Inc. (Amendment)

      SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)

      2/14/24 2:23:06 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Bellicum Pharmaceuticals Inc. (Amendment)

      SC 13D/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)

      11/24/23 1:43:27 PM ET
      $BLCM
      Biotechnology: Pharmaceutical Preparations
      Health Care